Results 111 to 120 of about 2,738 (166)

The German Lipoprotein Apheresis Registry (GLAR) - almost 5 years on. [PDF]

Clin Res Cardiol Suppl, 2017
Schettler VJJ, Neumann CL, Peter C, Zimmermann T, Julius U, Roeseler E, Heigl F, Grützmacher P, Blume H, Vogt A, Scientific Board of GLAR for the German Apheresis Working Group.   +10 more
europepmc   +1 more source

Managing Progressive Atherosclerotic Cardiovascular Disease in a Patient with Elevated Lipoprotein(a). [PDF]

Anatol J Cardiol
Yurtseven E, Tokgözoğlu L.
europepmc   +1 more source

Clinical and genetic characterization of homozygous <i>LDLR</i> variants in familial hypercholesterolaemia: insights from two case reports. [PDF]

Eur Heart J Case Rep
Sahoo SK, Singh PK, Barik R, Prakash S, Sahoo D, Mohanty CR, Malla SR, Mohapatra RK.   +7 more
europepmc   +1 more source

Lipoprotein Apheresis - Own Experience

Annals of Medical and Health Sciences Research, 2020
openaire  

Some of the next articles are maybe not open access.

Related searches:

Lipoprotein Apheresis

Endocrinology and Metabolism Clinics of North America, 2015
Patients with familial hypercholesterolemia (FH) have early development of atherosclerosis and cardiovascular disease (CVD). Lipid level-lowering medications are not always successful in reducing increased low-density lipoprotein C (LDL-C) levels. Lipoprotein apheresis (LA) therapy has proven its clinical benefit in reducing CVD events for patients ...
Patrick M, Moriarty, Linda, Hemphill
  +8 more sources

Effects of Lipoprotein apheresis on the Lipoprotein(a) levels in the long run

Atherosclerosis Supplements, 2015
Lipoprotein(a) (Lp(a)) is a low density lipoprotein-like particle to which apolipoprotein(a) is bound. It is recognized as an atherosclerosis-inducing risk factor. Up to now a detailed description of the effect of Lipoprotein apheresis (LA) on Lp(a) levels in the long run is lacking.We studied 59 patients with elevated Lp(a) levels who were treated ...
B Hohenstein, Eitan Gross
exaly   +3 more sources

Lipoprotein apheresis for lipoprotein(a) and cardiovascular disease

Journal of Clinical Lipidology, 2019
Elevated lipoprotein(a) [Lp(a)] is an independent risk factor for cardiovascular disease (CVD). In the United States, lipoprotein apheresis (LA) therapy is approved for patients with familial hypercholesterolemia. Germany uses LA therapy for patients with an Lp(a) > 60 mg/dL, normal low-density lipoprotein cholesterol (LDL-C) levels, and CVD.
Patrick M Moriarty
exaly   +3 more sources

Lipoprotein(a) apheresis

Current Opinion in Lipidology, 2016
Purpose of review Currently, different methods for extracorporeal elimination of atherogenic apolipoprotein B100 containing lipoprotein particles are used in clinical practice. Most of them effectively remove both lipoprotein(a) [Lp(a)] and LDL.
Sergei N, Pokrovsky, Olga I, Afanasieva, Marat V, Ezhov   +2 more
openaire   +2 more sources